Nailbiter1 wrote: I would also like to address another point.
I am ticked, like everybody else, at how slow things are moving and how many changes we have made.
I used to sneak behind the CEO's back and dig for information and got repromanded.
Now I wait for material news to come out and leave it to Tripp to inform.
We started with individual testing and family practices. That ended up being too costly and got partially dropped. Coastal Medical was helping with that. They are still involved but to what degree, we don't know.
The change of company name held us back, But you have to agree, StageZero Life Sciences defines us way better than Genenews. The website is expanding and looks more prof than the ond Gen site.
We are hiring personnel.
Oncore is in the picture to help us with yet another transitional stage but since they got on board, we signed with a behemoth... Mercer. Another change.
Oncore will still help but might not deliver the punch Mercer will.
Firefighters and first responders are coming to light in Georgia
We are signed with 3 or 4 telemed platforms that we know of, how many are unknown?
We just found out about UdoTest.
We are all set up for the delivery but the product is not on the shelf.
Rest assured, Once we are all out there, flappin' in the wind, our digital mark will be seen.
I know they will work on a system where, when you querry "Cancer Detection" we will show up front and centre. We are lost in the search engines of the world right now but we don't have Aristotle on the shelf yet.
We are doing all the underground nitty-gritty so when the Toga God steps up, we won't bottle-neck.
I'm so friggin' tired of waiting for our golden goose but it will come.
I would rather be set up and ready to deliver than to deliver and have it all cave in because we didn't prepare.
Build the track before you get the train, put the horse before the cart.
I wait and hold and buy the dips.
I have sold some .035 buys when we hit .18 but ended up buying more at .07
Call me a bag holder if it makes you smile but I would rather have a bag than not.
If you're a flipper, wait for covid, you'll have plenty of chances.
I am waiting for cancer to call and I'll answer with a bag full.
Peace.
Nailbiter1 wrote: gebremeskel, it's a different story now. We used to have 4 tests. Early CDT Lung, which belongs to Oncimmune in the UK. That company has been sold and somebody else owns rights to the US. It is gone now.
We have PHI, which is a Beckman Coulter test.
We have BreastSentry, which is a partnership with Sphingotek of Germany.
Finally we have ColonSentry which is 100% ours. Aristotle has improved that test exponentially. Now it detects left and right side of the colon, one of which is not visible with colonoscopy. It also can now detect from polyps stage, before it even becomes cancerous.
Aristotle will detect 10 cancers from one sample. Cancer is just phase one of Aristotle. There are 4 other phases in development.
"We will also explore the application of Aristotle to multiple disease states in Neurology, Gastroenterology, Cardiology, and Autoimmune Disorders.”
It's all based on the same (and now improved) mRNA tech.
Imagine finding out that you have MS or IBS/Crohn's or Alzheimer's years before the symptoms show up.
How would that change your life? What plans could you make to offset the disease?
Phase 1 cancer comes out this year. Other phases are probably being explored right now. That is the difference.
Nobody is interested in 3 tests that don't belong to us. When this thing rolls out, you want to be in it at penny level.
Aristotle Breast detection is superior to the Sphingotek one we have now.
Aristotle Prostate is superior to PHI.
Aristotle lung is superior to Early CDT... By far.
Aristotle is coming out second half of 2020. All of Tripps interviews and conferences and ASCO publication mention Aristotle, not "Gary the Prostate".
Lithium batteries powered drills and lawn mowers, now, bigger and better, they power 18 wheel semis. The past is the past. Don't let it rule the future.
Not a pump, you can look it all up yourself.
It's been a long time coming. It took years to develop the telehealth infrastructure. It's done now and expanding.
During this pandemic, telehealth/telemed is gaining more and more in popularity.
Not saying you should invest, DYODD and decide for yourself.
Now add the surprising and disastrous gift of an mRNA disease delivered by an mRNA virus. That one fell into our laps. The timing is unprecedented.
Peace. gebremeskel wrote: That all sounds great. But ColonSentry sounds great too. Why haven't they been able to sell it? And having failed to successfully market it why haven't they offered some sort of explanation for that failure and some hope for its future success? If they can't sell ColonSentry how do we know they will be able to sell Aristotle, no matter how amazing it sounds? Of course investing in a penny stock is a risky business, but still, management needs to give investors a clear understanding of what's going on and a reasonable basis for hope in the future value of the stock.
LithLover wrote: That they are 1 week away from closing the offering of $3.5- 8 million and with that they plan to ramp up the lab to take advantage of the millions in potential revenue from Covid testing and millions from rolling out Aristotle cancer testing:
The Company’s cash on hand, combined with the net proceeds from the Minimum Offering, is expected to be sufficient to fund the Company’s operations until at least June 30, 2021. The Company also expects to receive revenue from the sale of COVID-19 Tests and early cancer diagnostic tests. The Company intends to use the net proceeds of the Offering in a manner consistent with its business objective of expanding capacity to offer and conduct COVID-19 testing and development of its existing product lines, including Aristotle® . Specifically, the Company expects to incur approximately $3,040,000 in costs to fund the following objectives by the following dates:
Hiring new full-time laboratory staff. The Company intends to hire additional full-time laboratory staff to expand COVID-19 testing capabilities at the Richmond Laboratory. Under the Minimum Offering scenario, the Company intends to hire three (3) additional full-time laboratory staff members (this will be approximately $180,000 in costs, $nil of which is expected to be paid from existing cash on hand). Under the Maximum Offering scenario, the Company will hire nine (9) additional full-time laboratory staff with greater educational and experiential credentials including a Chief Science Officer (instead of three (3) fulltime employees under the Minimum Offering scenario) (this will be approximately $630,000 in costs, $nil of which is expected to be paid from existing cash on hand). This objective is expected to take approximately three (3) months.
Purchase Equipment, Test Reagents, and Consumable Materials. The Company must purchase equipment, test reagents, and consumable materials to expand COVID-19 testing capabilities and for further Aristotle® product development. Under the Minimum Offering scenario, this will be approximately $505,000 in costs, $150,000 of which is expected to be paid from existing cash on hand. This objective is expected to take approximately three (3) months.
Product Development and New Equipment Purchases. The Company intends to use proceeds of the Offering to develop its current product line and purchase equipment associated with product development and testing. Under the Minimum Offering scenario, this will be approximately $100,000 in costs, $50,000 of which is expected to be paid from existing cash on hand. This objective is expected to take approximately six (6) months.
--------------
Sonu12 wrote:
what does this mean for the stock long term please someone explain thank you